Articles related to CLINICAL STUDY

The authors present the findings of a large retrospective cohort study that used national data from the SEER-Medicare-linked database to better understand the relationship between antibiotics and PDAC survival. They discovered that perichemotherapy antibiotics were associated with improved survival in patients treated with first-line gemcitabine but not fluorouracil, implying that perichemotherapy antibiotic treatment may have a role in patients with metastatic PDAC receiving gemcitabine. Prospective studies on the effect of perichemotherapy antibiotics with high pancreatic penetration and gram-negative coverage on survival in diverse populations of patients with metastatic PDAC treated with gemcitabine are recommended.

Twelve-hundred (1,200) patients admitted for 48 hours or more for COVID were randomized to 2.5mg of apixaban or placebo twice daily for 30 days. The incidence of death or thromboembolism was low and similar in the two arms of this study. The study was terminated early and the authors say the results are imprecise.

In a study population of nearly 3.25 million adults receiving COVID boosters from November 2021 through February 2022, the 20-week risk per 1,000 for contracting COVID was 164.2 for the Pfizer-BioNTech vaccine and 159.9 for the Moderna vaccine.

Drawing from animal evidence that aging and metabolic dysfunction result in depletion of NAD+ within neurons, B3 supplementation of 500mg BID for 6 weeks was studied as a means of increasing available NAD+. As published in Nature, a small but significant increase in NAD+ available to neurons was seen with B3 supplementation.

Two-hundred sixteen (216) people with mild-to-moderate disease were treated with 100 mg simufilam tablets twice daily for 12 months. ADAS-Cog-11 score showed a “highly desirable” overall minimal decline in cognitive ability after one year. Simufilam is an oral small molecule designed to to prevent beta and tau amyloid clumping by correctong an altered form of filamin A.

A faulty control arm makes a new trial for tricuspid valve regurgitation intervention seem positive. But in reality, the results probably aren’t.